• QuantaLife receives grant to develop technology for MSRA detection

    Polymerase chain reaction (PCR) developer QuantaLife has received a National Institutes of Health (NIH) grant totaling ~$6 million over five years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections.
    Sept. 14, 2010

    Polymerase chain reaction (PCR) developer QuantaLife (Pleasanton, CA) has received a National Institutes of Health (NIH) grant totaling ~$6 million over five years for the development of rapid, cost-effective technology for detecting methicillin-resistant Staphylococcus aureus (MRSA) infections. The grant, from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the NIH, will fund the project.

    QuantaLife is currently building a new instrument system for droplet digital PCR that will detect and quantify DNA/RNA targets. The NIH grant will allow the company to broaden its product pipeline to build a platform for detecting the antibiotic-resistant bacteria that cause MRSA infections. Clinical testing will be done in collaboration with the University of Mississippi Medical Center.

    Source: PR Newswire

    Posted by Lee Mather

    Follow us on Twitter

    Subscribe now to BioOptics World Magazine; it's free!

    Sign up for Laser Focus World Newsletters
    Get the latest news and updates.

    Voice Your Opinion!

    To join the conversation, and become an exclusive member of Laser Focus World, create an account today!